Preserved supervised synthesis

Pemvidutide synthesis · version 1

This URL preserves the exact reviewed public wording and source set for synthesis version 1.

Supervised synthesis

What do selected human studies report about Pemvidutide?

Manually reviewed September 15, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

Two selected reports examine liver-fat changes during an extension study and histologic outcomes in a phase 2 trial. The extension continues an earlier participant cohort; it is not a separate randomized trial.¹²

Bottom line from this bounded source set

The extension reported liver-fat reductions among selected continuing participants. IMPACT met its MASH-resolution endpoint at 24 weeks but did not demonstrate its fibrosis-improvement endpoint. Longer-term clinical outcomes remain unestablished.¹²

Reviewed study record

MASLD extension

Design

Double-blind extension of a preceding randomized trial; NCT05292911.¹

Population

64 participants from the earlier 94-participant study continued; this is not a new independently randomized cohort.¹

Outcomes reported

At 24 weeks, reported relative liver-fat reductions were 56.3%, 75.2% and 76.4% in active groups versus 14.0% with placebo.¹

Limitations

Selective extension participation can bias interpretation. MRI liver fat is not the same as histologic fibrosis improvement or patient-important liver outcomes.¹

Reviewed study record

IMPACT: biopsy-confirmed MASH

Design

Randomized, double-blind, placebo-controlled phase 2 trial; NCT05989711; two coprimary histology endpoints at week 24.²

Population

212 participants with MASH and stage F2 or F3 fibrosis participated.²

Outcomes reported

The study met the endpoint of MASH resolution without worsening fibrosis, but did not meet the fibrosis-improvement endpoint without worsening MASH. Adverse events were reported in 78% and 81% of active groups versus 67% with placebo.²

Limitations

The abstract does not fully describe handling of missing biopsy outcomes. Longer follow-up was ongoing; a favorable disease-activity endpoint does not establish fibrosis benefit or fewer clinical events.²

Reviewed source set

PubMed · 41113119Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. ↗PubMed PMID 41113119 · EFetch XML reviewed 2026-09-15 · payload SHA-256 d02cc11ccdebbc2d2d7f2dcd803d72fac82dab958b1ca103096a9f2b94a061c5
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/j.jhepr.2025.101483. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
PubMed · 41237796Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. ↗PubMed PMID 41237796 · EFetch XML reviewed 2026-09-15 · payload SHA-256 dc020308c93198cfa3c4163c9eb9c575c301825253480a1bfa07d377614feda9
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(25)02114-2. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗